Alopecia

Latest News

The authors recommend incorporating more SoC-specific imagery and case discussions into dermatology curricula, along with a stronger emphasis on biopsy in unclear cases. | Image Credit: Prostock-studio - stock.adobe.com
High Rates of Misdiagnosis in Hair, Scalp Disorders Among Patients With Skin of Color

August 13th 2025

Hair and scalp disorders in patients with skin of color are frequently misdiagnosed, often due to educational gaps and premature diagnosis, with scalp biopsy proving more reliable than trichoscopy for accurate diagnosis.

The new data are from one of 2 pivotal phase 3 trials designed to study the safety and efficacy of upadacitinib in adults and adolescents with severe AA. | Image Credit: Yurii Kibalnik - stock.adobe.com
Upadacitinib Shows Strong Efficacy in Phase 3 Alopecia Areata Trial

August 7th 2025

Though it would seem surprising for alopecia therapies with overlapping targets to lead to different patient outcomes, the authors said the evidence suggests the strategy can work. | Image credit: Nadya Kolobova - stock.adobe.com
New Strategies and Combinations Could Help Address AA Relapse

August 1st 2025

The new report evaluated how alopecia areata affects mental health across cultural and national borders. | Image credit: melita - stock.adobe.com
Links Between Alopecia and Mental Health Vary by Country

July 21st 2025

The JAKis evaluated were effective in a dose-dependent manner, the study found. | Image Credit: Victoria - stock.adobe.com
Analysis Highlights Comparative Efficacy of Alopecia Areata Drugs

July 18th 2025

More News

Physician prescribing AA treatment to patient | Image Credit: buritora - stock.adobe.com
February 17th 2024

Patient, Physician Viewpoints Differ Regarding AA Severity, Treatment Satisfaction

Cameron Santoro
A Japanese study of alopecia areata (AA) found misalignment between patient and doctor perceptions of severity, limiting treatment options, and leading to dissatisfaction and unmet needs.
Alopecia surrounded by medication | Image Credit: greenapple78 - stock.adobe.com
February 14th 2024

Targeting T-Cell–Based Therapies to Treat Alopecia Areata

Cameron Santoro
New research explores T cells and their signaling pathways in alopecia areata (AA), highlighting promising drug targets for future treatment.
Doctor reviewing medical research | Image Credit: Geber86 - stock.adobe.com
February 9th 2024

Study Finds AA Associated With Connective Tissue, Ocular Diseases and Vitamin D Deficiency

Cameron Santoro
Meta-analysis results identify high and low associations of various comorbidities like vitamin D deficiencies, ocular diseases, among others in patients with alopecia areata (AA), to promptly manage and improve treatment outcomes.
Doctor using magnifying glass to view scalp regrowth | Image Credit: Elnur - stock.adobe.com
February 7th 2024

Study Finds Significant Hair Regrowth in Patients With Patchy AA Following Baricitinib Treatment

Cameron Santoro
Baricitinib was found to be an effective treatment for patchy alopecia areata (AA), in a retrospective study, with most patients experiencing hair regrowth after 4 to 16 weeks of treatment.
Hair loss treatment medicines | Image Credit: KenamiRyoko- stock.adobe.com
January 29th 2024

AA Treatment: Comparing Topical Treatments, Microneedling, Tofacitinib

Cameron Santoro
Topical treatments and minoxidil solutions were found to be the most effective, safe, and affordable first-line options for treating pediatric AA.
Worried woman looking at scalp | Image Credit: Pormezz - stock.adobe.com
January 25th 2024

Tofacitinib as AA Treatment Has High Drug Survival Rates, Manageable Side Effects

Cameron Santoro
A study from China found that tofacitinib was an effective treatment for alopecia areata (AA), with most patients achieving complete or partial hair regrowth and experiencing tolerable side effects.
Doctor examining child's scalp | Image Credit: New Africa - stock.adobe.com
January 20th 2024

Topical Corticosteroids: The Preferred First-Line Treatment for Pediatric Alopecia Areata

Cameron Santoro
A survey of pediatric dermatologists revealed that topical corticosteroids are the most common first-line treatment for children with alopecia areata, regardless of age or hair loss severity.
Itchy scalp with braids | Image Credit: Andrey Popov - stock.adobe.com
January 18th 2024

Evaluating Hair Camouflage as a Tool for Black Women With Alopecia: A Critical Review

Cameron Santoro
Black women with alopecia often struggle between concealing their hair loss and protecting their fragile scalps, all while seeking to express their cultural identity and build self-confidence.
Woman worried about hair loss | Image Credit: Andrey Popov - stock.adobe.com
January 13th 2024

Disparities in Clinical Trial Enrollment, Retention Among Marginalized Racial and Ethnic Groups With AA

Cameron Santoro
A US study found alopecia areata (AA) is more common in non-White patients, likely due to underrepresentation in dermatology, leading to less consideration of AA as a diagnosis for non-White individuals.
Alopecia hair loss in hair brush, medical syringe | Image Credit: Nadzeya - stock.adobe.com
January 12th 2024

Hair Regrowth in Severe Alopecia Areata Improves Quality of Life While Reducing Anxiety, Depression

Cameron Santoro
People with alopecia areata who experience hair regrowth may also see improvements in their quality of life and mental health, according to a new study.
Man with bald patches - alex papp - adobe.stock.com
December 20th 2023

Most US Dermatologists Prescribe Baricitinib for Alopecia Areata, Report Shows

Emma Andrus
Baricitinib is more commonly prescribed by dermatologists for patients with alopecia in the United States and is projected to maintain a substantial market lead over ritlecitinib.
Hair loss | Image Credit: Nadya Kolobova - stock.adobe.com
November 29th 2023

Out-of-Pocket Spend Imposes Significant Economic Burden in Alopecia

Maggie L. Shaw
A new analysis evaluated the economic implications of alopecia on women and their families, with significant out-of-pocket expenses attributed to treatments and measures to conceal the condition.
Person cupping ear to hear better | Image credit: steph photographies - stock.adobe.com
November 22nd 2023

Study Confirms Link Between Alopecia Areata and Hearing Loss

Skylar Jeremias
The presence of cochlear dysfunction found in patients with alopecia areata (AA) suggests the need for more comprehensive assessment and management of hearing-related issues associated with AA.
Alopecia areata in a young girl | Image credit: Nadya Kolobova - stock.adobe.com
November 14th 2023

Pharmacists Can Advise Patients With Androgenetic Alopecia

Yvette C. Terrie, BSPharm, RPh
Pharmacists play a role in advising patients with hair loss about self-management and proper application of over the counter products.
Close up of a woman's eyes | Image credit: Artem Markin - stock.adobe.com
November 5th 2023

Understanding Eyebrow and Eyelash Hair Loss in Severe Alopecia Areata

Lauren Buchanan, MA
The distribution of eyebrow and eyelash hair loss in relation to the severity of scalp hair loss remains underexplored, and this study established baseline characteristics.
Pill bottle.
October 1st 2022

Oral Administration of JAK Inhibitors Shows Improved Response in Alopecia Areata

Matthew Gavidia
Patients with alopecia areata showed improved response rate with oral Janus kinase (JAK) inhibitors vs topical and sublingual JAK inhibitor administration.
Doctor and patient consult.
September 8th 2022

Shared Decision-Making Linked With Improved Treatment Satisfaction in Alopecia Areata

Matthew Gavidia
Patients with alopecia areata were less likely to report decisional regret regarding treatment when dermatologists incorporated shared decision-making, with prescription of Janus kinase (JAK) inhibitors associated with the lowest decisional regret.
Globe.
August 11th 2022

Disease Burden of Alopecia Areata Greater in Lower-Income Countries

Matthew Gavidia
Despite decreasing trends observed in the global burden of alopecia areata, low-income countries and ​​Western Sub-Saharan Africa regions continue to exhibit rising incidence and disability-adjusted life-years rates.
<123

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo